Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells + platelet-rich plasma
- Development stage
- Unknown
- Lead developer
- Yantai Yuhuangding Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Autologous bone marrow-derived mesenchymal stem cells (BMSCs) plus autologous platelet-rich plasma (PRP) is a combination cell therapy developed by Yantai Yuhuangding Hospital for the treatment of severe knee osteoarthritis. The therapeutic process involves aspirating bone marrow from the patient's iliac crest to isolate and culture BMSCs. Simultaneously, PRP is prepared from the patient's peripheral blood through centrifugation. The cultured BMSCs are then suspended in the PRP and administered via intra-articular injection. This treatment leverages the regenerative and immunomodulatory properties of mesenchymal stem cells alongside the concentrated growth factors found in PRP to promote cartilage repair, reduce inflammation, and improve joint function in patients with degenerative joint disease.
- Other names
- Autologous BMSCs plus autologous PRPAutologous bone marrow-derived mesenchymal stem cells suspended in PRPAuotologous BMSCs plus autologous PRP
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells + platelet-rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells + platelet-rich plasma.